Co-treatment with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs) elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property

International Journal of Cardiology

Volumn 146, Issue 2, 2011, Pages 264-266

  Maeda, Sayaka ^a   Matsui, Takanori ^a   Takeuchi, Masayoshi ^b   Yamagishi, Sho Ichi ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b HOKURIKU UNIVERSITY   (Japan)

Author keywords

Adiponectin; AGEs; Azelnidipine; Olmesartan

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; AZELNIDIPINE; MESSENGER RNA; OLMESARTAN;

ADIPOCYTE; ANTIOXIDANT ACTIVITY; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; HEPATOMA CELL; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LETTER; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

EID: 78651463149     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.10.073     Document Type: Article

References (15)

1. S. Yamagishi, and T. Imaizumi Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy Curr Pharm Des 11 2005 2279 2299
2. N. Tahara, S. Yamagishi, and T. Matsui Serum levels of advanced glycation end products (AGEs) are independent correlates of insulin resistance in non-diabetic subjects Cardiovasc Therap 2010 10.1111/j.1755-5922.2010.00177.x
3. M. Takeuchi, and S. Yamagishi Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease J Alzheimers Dis 16 2009 845 858
4. Unoki H, Yamagishi S (2008) Advanced glycation end products and insulin resistance. Curr Pharm Des 2009;14:987-9.
5. T. Yoshida, S. Yamagishi, and K. Nakamura Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation Horm Metab Res 40 2008 620 625
6. F. Ziemke, and C.S. Mantzoros Adiponectin in insulin resistance: lessons from translational research Am J Clin Nutr 91 2010 258S 261S
7. S. Shetty, C.M. Kusminski, and P.E. Scherer Adiponectin in health and disease: evaluation of adiponectin-targeted drug development strategies Trends Pharmacol Sci 30 2009 234 239
8. Y. Hattori, K. Akimoto, S.S. Gross, S. Hattori, and K. Kasai Angiotensin-II-induced oxidative stress elicits hypoadiponectinaemia in rats Diabetologia 48 2005 1066 1074
9. S. Yamagishi, M. Takeuchi, and H. Inoue Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats Int J Tissue React 27 2005 137 143
10. S. Yamagishi, Y. Inagaki, K. Nakamura, and T. Imaizumi Azelnidipine, a newly developed long-acting calcium antagonist, inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endothelial cells through its anti-oxidative properties J Cardiovasc Pharmacol 43 2004 724 730
11. S. Yamagishi, T. Matsui, and K. Nakamura Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species Ophthalmic Res 40 2008 10 15
12. S. Yamagishi, M. Takeuchi, and H. Inoue Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (age)-injected rats Drugs Exp Clin Res 31 2005 45 51
13. S. Yamagishi, K. Nakamura, and T. Matsui Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression J Biol Chem 281 2006 20213 20220
14. S. Yamagishi, T. Matsui, H. Adachi, and M. Takeuchi Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population Pharmacol Res 61 2010 103 107
15. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150